Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.
Richard D. Kim, MD, a medical oncologist within the Department of Gastrointestinal Oncology at Moffitt Cancer Center and an assistant professor of oncology with University of South Florida College of Medicine, discusses the evolving treatment landscape of advanced hepatocellular carcinoma (HCC).
Since the approval of sorafenib (Nexavar) in 2007, the treatment landscape of advanced HCC remained largely unchanged, Kim explains.
However, the May 2020 approval of atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) for patients with unresectable or metastatic HCC transformed the paradigm and introduced a new frontline standard of care, says Kim.
The approval was based on findings from the IMbrave150 trial in which the combination elicited a 42% reduction in the risk of death compared with sorafenib.
Additionally, other novel agents have been approved in the second-line setting to further expand the options that are available to patients with advanced HCC, Kim concludes.